1. Home
  2. FSP vs SCYX Comparison

FSP vs SCYX Comparison

Compare FSP & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Street Properties Corp.

FSP

Franklin Street Properties Corp.

N/A

Current Price

$0.33

Market Cap

48.2M

Sector

Real Estate

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

N/A

Current Price

$4.33

Market Cap

51.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FSP
SCYX
Founded
1981
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.2M
51.4M
IPO Year
2001
2014

Fundamental Metrics

Financial Performance
Metric
FSP
SCYX
Price
$0.33
$4.33
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
645.1K
59.6K
Earning Date
04-28-2026
05-06-2026
Dividend Yield
6.34%
N/A
EPS Growth
15.69
61.36
EPS
N/A
N/A
Revenue
$107,162,000.00
$257,000.00
Revenue This Year
$17.91
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$0.57
52 Week High
$1.71
$6.09

Technical Indicators

Market Signals
Indicator
FSP
SCYX
Relative Strength Index (RSI) 26.10 36.28
Support Level N/A $0.67
Resistance Level $0.41 $5.56
Average True Range (ATR) 0.02 0.29
MACD -0.01 -0.14
Stochastic Oscillator 0.50 0.00

Price Performance

Historical Comparison
FSP
SCYX

About FSP Franklin Street Properties Corp.

Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: